Takeda and GSK Challenge Latest Data Linking TZDs To Cardiovascular Events
This article was originally published in PharmAsia News
Executive SummaryTakeda and GlaxoSmithKline are disputing the findings of a Canadian study published in the December 12 issue of the Journal of the American Medical Association linking thiazolidinediones to cardiovascular events
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).